Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Suresht Sharma

Gastroenterology West Covina, CA Medical Doctor

NPI 1194766196 CMS profile 53647

1135 S Sunset Ave, Suite 405, West Covina, CA 91790

Open in the dashboard

General payments

$2,521

134 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Suresht Sharma of West Covina, CA is reported in the CMS Open Payments database as having received $2,521 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $15 1
2023 General $419 22
2022 General $668 31
2021 General $696 35
2020 General $232 12
2019 General $490 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suresht Sharma
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Suresht Sharma were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Suresht Sharma Gastroenterology median Middle half National median
2019 $490 $417 $126–$1,100 $163
2020 $232 $224 $74–$624 $114
2021 $696 $352 $106–$1,054 $132
2022 $668 $448 $129–$1,270 $149
2023 $419 $533 $150–$1,390 $160
2024 $15 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $1,280 63 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $241 13 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $163 9 payments
  4. Gilead Sciences, Inc. $152 9 payments
  5. Ardelyx, Inc. $106 5 payments
  6. GlaxoSmithKline, LLC. $101 7 payments
  7. QOL Medical, LLC $92 5 payments
  8. Merck Sharp & Dohme Corporation $67 4 payments
  9. Celgene Corporation $60 4 payments
  10. Phadia US Inc. $53 3 payments
  11. Other $204 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,500 133 payments
  2. Consulting Fee $21 1 payment
Products named General payments · program years 2019–2024
  1. CREON $698 35 payments
  2. LINZESS $593 31 payments
  3. RINVOQ $265 11 payments
  4. HUMIRA $178 9 payments
  5. SKYRIZI $163 9 payments
  6. XIFAXAN $143 8 payments
  7. ENTYVIO $114 4 payments
  8. IBSRELA $106 5 payments
  9. BENLYSTA $101 7 payments
  10. Sucraid $92 5 payments
  11. Other $805 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record